Where does Gilgamesh Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Gilgamesh Pharmaceuticals, Inc. ranks #47,060 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Gilgamesh Pharmaceuticals, Inc. hold?

Gilgamesh Pharmaceuticals, Inc. holds 5 US utility patents granted between 2022 and 2024, spanning 5 technology areas.

What is Gilgamesh Pharmaceuticals, Inc.'s Innovation Score?

Gilgamesh Pharmaceuticals, Inc. has an Innovation Score of 43.0 out of 100 (top 29% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Gilgamesh Pharmaceuticals, Inc. focus on?

Gilgamesh Pharmaceuticals, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 5 patents, ranking #1,402 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Gilgamesh Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Gilgamesh Pharmaceuticals, Inc..

What does claim depth mean for Gilgamesh Pharmaceuticals, Inc.'s patents?

Gilgamesh Pharmaceuticals, Inc.'s patents average 14.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Gilgamesh Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Gilgamesh Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Gilgamesh ranks #47,060 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.

#47,060
of 49,997 US assignees by volume: Top 29%
by Innovation Score (43.0/100): 14.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R47060 · US Corporation #47,060 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #47,060/49,997
PHOTO-FINISH Giffin Tec
CPC-NARROW C07D · 5 areas
INNOV-PAR 43.0/100
CLAIMS-RICH 14.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2024 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Giffin Tec, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Gilgamesh’s 43.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (14%) Velocity 20.0 pts (47%) Breadth 7.9 pts (18%) Claim depth 8.9 pts (21%)

Qualcomm Incorporated · highest

85
Gilgamesh Pharmaceut… · this assignee

43
3D Lighting… · lowest

7

What this shows Gilgamesh's Innovation Score is 43.0/100 (top 29% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Gilgamesh?

Each dot is one of Gilgamesh’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Gilgamesh’s own 14.8 claims/patent is at or below the 17.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Gilgamesh vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Gilgamesh's grants concentrate

Gilgamesh Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (3 grants) versus a trough of 2 in 2022. By volume, Gilgamesh sits between Giffin Tec, Inc. and Glass Dynamics, Inc..

Gilgamesh's three-year grant acceleration

Gilgamesh Pharmaceuticals, Inc. shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Giffin Tec

5
Gigsky

5
Gigadevice Semico…

5
Gigajot

5
Gill Industries

5
Gitlab

5
Glabete

5
Glass Dynamics

5
Gilgamesh Pharmac… ◀

5

What this shows Gilgamesh holds 5 patents at rank #47,180, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gilgamesh

By rank, the assignees closest to #47,180 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Gilgamesh's primary technology class.

Gilgamesh's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Gilgamesh Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	40.0%
2024	3	60.0%

Which technologies does Gilgamesh Pharmaceuticals, Inc. patent most?

C07D - Heterocyclic Compounds 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

C07C - Acyclic OR Carbocyclic Compounds 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Gilgamesh Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Gilgamesh Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #47,060 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Gilgamesh Pharmaceuticals, Inc. against Giffin Tec, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.